SQZ Biotech to Present at Upcoming Investor Conferences in November & December


WATERTOWN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will present a corporate overview at the Stifel 2019 Healthcare Conference in New York City, the Jefferies 2019 London Healthcare Conference in London, United Kingdom, and the Evercore ISI HEALTHCONx Conference in Boston.

Stifel 2019 Healthcare Conference
Date:  Tuesday, November 19
Time:  9:45am ET
    
Jefferies 2019 London Healthcare Conference
Date:  Thursday, November 21
Time:  7:20am GMT
    
Evercore ISI HEALTHCONx Conference
Date:  Tuesday, December 3
Time:  9:30am ET

About SQZ Biotech
SQZ Biotech is a privately held, clinical-stage company creating innovative treatments by transforming cells into sophisticated therapeutics. Using its proprietary platform, SQZ has the unique ability to precision engineer virtually any cell type and deliver multiple materials, potentially resulting in powerful, multifunctional cell therapies for a range of diseases with an initial focus on cancer and autoimmune disease. The company’s initial applications leverage SQZ’s ability to generate target-specific immune responses, both in activation for the treatment of solid tumors, and immune suppression for the treatment of immune reactions and diseases. For more information please visit www.sqzbiotech.com.

SQZ Contact:
Rebecca Cohen
Senior Manager, Corporate Relations
rebecca.cohen@sqzbiotech.com
617-758-8672 ext. 728

Media Contact
Cait Williamson, PhD
LifeSci Public Relations
cait@lifescipublicrelations.com
646-751-4366